Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity

Summary

Incyte President and CEO Bill Meury joins Fast Money to discuss the company's plan to offset the 2028 Jakafi patent cliff. He points to core business growth, seven prioritized pipeline programs supported by 14 Phase 3 trials, and three targeted blood cancer therapies as central to Incyte's identity. He also highlights two solid tumor programs and the company's growing balance sheet as M&A firepower.

• Incyte faces loss of Jakafi exclusivity in 2028 and aims to replace roughly $3 billion in revenue.
• Management has advanced seven programs backed by 14 Phase 3 trials and needs two or three winners.
• Three targeted blood cancer therapies are described as the company's central identity.
• Two solid tumor programs target pancreatic and colorectal cancers that have missed immuno-oncology progress.
• Incyte's balance sheet is expected to grow from about $3 billion to $5 billion by end-2026.
• CEO Bill Meury says M&A will be used for high-fit, durable assets, not to fill revenue gaps.
• He also mentions options like an FDA national priority voucher to accelerate development.